A new report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations, is the first to describe in detail the epidemiology, burden, and treatment of osteoporosis in all 27 member states of the European Union (EU27).
Published today in Rome in conjunction with the opening of Europe's largest osteoporosis congress, the report 'Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden' shows that as Europe's population ages, fractures due to osteoporosis will result in increasing costs, disability and premature deaths. Approximately 3.5 million new fragility fractures occur annually in the EU. In 2010 alone, fragility fractures resulted in costs of 37 billion.
Osteoporosis is a common condition that causes bones to become weak and fragile. People with osteoporosis are at high risk of breaking a bone, even after a minor fall, bump or a sudden movement. These fractures can have a huge impact on the sufferer, leading to substantial pain, disability and even premature death. Based on data collected in 2010, the report found that 22 million women and 5.5 million men in the EU27 have osteoporosis.
IOF President Professor John Kanis of the WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, stated, "It is very worrying that health systems are unprepared to meet the growing tide of fractures due to osteoporosis. High risk individuals are not being routinely identified and offered treatment. The current model of osteoporosis management is not sustainable as Europe's population ages and fracture incidence and costs increase still further."
Even people who have broken a bone due to osteoporosis and present to hospitals or clinics for care, are not being systematically diagnosed and treated to prevent further fractures. A first fracture doubles the risk of suffering another, making prevention of this kind critical. Safe and cost effective medications to reduce the risk of fracture are widely available throughout Europe. However, one of the startling findings of the report is that, despite the rising number of people in need of treatment, the actual number of patients taking preventive medication is declining.
"The low rate of diagnosis and treatment in high risk individuals is compounded by the fact that, even when prescribed, approximately 50% of patients do not follow their treatment regimen," said Professor Juliet Compston, Professor of Bone Medicine at the University of Cambridge and Chair of the European Osteoporosis Consultation Panel.
Professor Compston went on to say, "It is apparent that Europe's health authorities must make provision in their healthcare planning to deal with the increase in fractures and associated disability. Key elements of any national strategy must include the better implementation of national guidelines, the establishment of fracture liaison services to identify high-risk patients, and improvement of adherence to proven cost-effective treatment by patients."
The report will be available at http://link.springer.com/journal/11657 (open access); a summary of the report is available at http://www.iofbonehealth.org/osteoporosis-european-union-medical-management-epidemiology-and-economic-burden
Several of the key findings are:
|Contact: L. Misteli|
International Osteoporosis Foundation